Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $26.1 million.

  • Zevra Therapeutics' Total Current Liabilities fell 2427.13% to $26.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.1 million, marking a year-over-year decrease of 2427.13%. This contributed to the annual value of $34.1 million for FY2024, which is 5379.14% down from last year.
  • According to the latest figures from Q3 2025, Zevra Therapeutics' Total Current Liabilities is $26.1 million, which was down 2427.13% from $28.8 million recorded in Q2 2025.
  • In the past 5 years, Zevra Therapeutics' Total Current Liabilities registered a high of $73.7 million during Q4 2023, and its lowest value of $2.9 million during Q1 2022.
  • For the 5-year period, Zevra Therapeutics' Total Current Liabilities averaged around $20.5 million, with its median value being $18.3 million (2023).
  • As far as peak fluctuations go, Zevra Therapeutics' Total Current Liabilities tumbled by 9477.67% in 2021, and later soared by 51315.81% in 2023.
  • Quarter analysis of 5 years shows Zevra Therapeutics' Total Current Liabilities stood at $4.2 million in 2021, then surged by 184.23% to $12.0 million in 2022, then soared by 513.16% to $73.7 million in 2023, then plummeted by 53.79% to $34.1 million in 2024, then dropped by 23.35% to $26.1 million in 2025.
  • Its last three reported values are $26.1 million in Q3 2025, $28.8 million for Q2 2025, and $27.0 million during Q1 2025.